November 24, 2016 - By Ellis Scott · 0 Comments
The stock of Alimera Sciences Incorporated (NASDAQ:ALIM) registered a decrease of 23.48% in short interest. ALIM’s total short interest was 763,700 shares in November as published by FINRA. Its down 23.48% from 998,100 shares, reported previously. With 194,900 shares average volume, it will take short sellers 4 days to cover their ALIM’s short positions. The short interest to Alimera Sciences Incorporated’s float is 2.56%. The stock decreased 2.63% or $0.03 on November 23, hitting $1.11. About 241,202 shares traded hands. Alimera Sciences Inc (NASDAQ:ALIM) has declined 56.81% since April 22, 2016 and is downtrending. It has underperformed by 62.22% the S&P500.
Alimera Sciences, Inc. is a pharmaceutical company. The company has a market cap of $70.15 million. The Firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It currently has negative earnings. The Firm operates through two divisions: U.S. and International.
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.48, from 0.52 in 2016Q1. The ratio increased, as 14 funds sold all Alimera Sciences Inc shares owned while 19 reduced positions. 10 funds bought stakes while 7 increased positions. They now own 20.32 million shares or 19.64% less from 25.29 million shares in 2016Q1.
Bessemer Grp Inc last reported 0% of its portfolio in the stock. Deutsche Bancorp Ag accumulated 121,069 shares or 0% of the stock. Ny State Common Retirement Fund, a New York-based fund reported 8,300 shares. National Bank & Trust Of Montreal Can owns 500 shares or 0% of their US portfolio. Manufacturers Life Ins The, a Ontario – Canada-based fund reported 2,405 shares. Tfs Cap Limited Liability Com, a Pennsylvania-based fund reported 17,305 shares. Parkwood Ltd Llc holds 0.05% of its portfolio in Alimera Sciences Inc (NASDAQ:ALIM) for 228,123 shares. Blackrock Inv Mgmt Lc has invested 0% of its portfolio in Alimera Sciences Inc (NASDAQ:ALIM). Walleye Trading Limited Liability Company accumulated 0% or 1,600 shares. Geode Management Ltd Liability Corp accumulated 145,751 shares or 0% of the stock. Paloma Ptnrs Mngmt Commerce holds 114,102 shares or 0% of its portfolio. National Bank & Trust Of Mellon holds 0% of its portfolio in Alimera Sciences Inc (NASDAQ:ALIM) for 25,294 shares. Orbimed Advsrs Limited Liability Company holds 250,000 shares or 0% of its portfolio. The Illinois-based Grp One Trading Lp has invested 0% in Alimera Sciences Inc (NASDAQ:ALIM). Southeast Asset Advsr accumulated 0% or 10,000 shares.
Insider Transactions: Since September 15, 2016, the stock had 0 buys, and 1 insider sale for $77,726 net activity. 51,471 shares were sold by EISWIRTH RICHARD S JR, worth $77,726.
Out of 2 analysts covering Alimera Sciences (NASDAQ:ALIM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alimera Sciences has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 12 report. Cantor Fitzgerald maintained it with “Buy” rating and $6 target price in Tuesday, January 19 report. Cowen & Co downgraded the stock to “Market Perform” rating in Friday, May 6 report. The firm earned “Outperform” rating on Friday, September 16 by Cowen & Co.
Alimera Sciences, Inc. (Alimera), incorporated on June 4, 2003, is a pharmaceutical company. The Firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Firm operates through two divisions: U.S. and International. The Firm focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More news for Alimera Sciences Inc (NASDAQ:ALIM) were recently published by: Reuters.com, which released: “Eye drug company Alimera Sciences mulls sale: sources” on December 17, 2015. Quotes.Wsj.com‘s article titled: “News Alimera Sciences Inc.ALIM” and published on February 11, 2011 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott